There has been a huge breakthrough in the treatment of prostate cancer with hormonal therapies and targeted radionuclide therapies such as 177Lu-PSMA and 225Ac-PSMA, but these are not yet widely available. Here, FOLH1 is linked to Familial prostate cancer.